Nachrichten zur atai Life Sciences B.V. Aktie

Atai Life Sciences stock hits 52-week high at $5.35 By Investing.com

Atai Life Sciences stock hits 52-week high at $5.35…

atai shares jump 10% on positive trial data for depression nasal spray

Shares in atai Life Sciences (NASDAQ:ATAI, ETR:9VC) rose 10% on Tuesday after the company and its UK partner Beckley Psytech reported…

atai Life Sciences and Beckley Psytech report positive mid-stage trial results for depression treatment

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech said Tuesday that their experimental nasal spray for depression showed promising results…

atai Life Sciences Awarded Grant from the National Institutes of Health

5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for…

atai Life Sciences secures NIH grant for opioid use disorder program

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has been awarded a grant of up to $11.4 million from the…

Atai Life Sciences CEO provides updates and outlines next steps for BPL-003 and other programs

…

Atai Life Sciences CEO provides updates and outlines next steps for BPL-003 and other program

…

Small cap wrap: Digi Power X, C3 Metals, atai Life Sciences...

…

atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a…

Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset

…

ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint By Investing.com

ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint…

atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company’s potential to...…

atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company’s potential to...…

atai Life Sciences (ATAI) Upgraded to Strong Buy: Heres Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade…

Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary

Sales of Johnson & Johnson (NYSE:JNJ)’s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for…

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far…

Amazon, Nike, DoorDash, atai Life Sciences and more analyst calls of the week

…

Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression

Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant...…

atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy’ for analysts at Jefferies, who continue to see significant upside ahead for…

Market movers: Marvell Technologies, atai Life Sciences, Compass Pathways...

…

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Lets…

atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the…

ATAI Life Sciences stock soars on Beckley Psytech merger deal By Investing.com

ATAI Life Sciences stock soars on Beckley Psytech merger deal…

atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday’s opening bell after it announced it has inked a definitive agreement…

atai Life Sciences and Beckley Psytech to merge in all-share deal

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage...…

atai Life Sciences expects key trial data by mid-2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress…

atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Lets…

atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytechs depression therapy

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later…

atai Life Sciences could double on positive data from Beckley Psytechs depression therapy: Jefferies

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later…

atai Life Sciences announces positive topline data from Phase 2a treatment-resistant depression study

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of…

atai Life Sciences announces positive topline data from treatment-resistant depression study

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of BPL-003, an…

atai Life Sciences shares gain momentum ahead of pivotal trial readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ stock is poised to climb significantly, driven by a series of clinical catalysts this year…

atai Life Sciences builds clinical momentum in first quarter of 2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key…

atai Life Sciences doses first patient in Phase 2 social anxiety trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of…

atai Life Sciences CEO discusses major data readouts expected through 2025

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the companys upcoming clinical milestones and strategic focus…

atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and…

atai Life Sciences entering catalyst-rich period, Jefferies says

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and…

atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as…

atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of…

atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech’s Phase 2b trial evaluating BPL-003…

atai Life Sciences completes public offering, raising $63.25M

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter’s option to…

atai Life Sciences announces pricing of $55M public offering of shares

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10…

atai Life Sciences unveils $55M public offering to advance mental health treatments

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The…

atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech’s Phase 2a…

atai Life Sciences reports new BPL-003 trial shows promise for AUD

…

atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout

Positive data from Irish biotechnology firm GH Research’s Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT),…

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

…

atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts

atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for…

atai Life Sciences unveils positive results from Beckley Psytech’s alcohol use disorder trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech’s Phase 2a study of BPL-003 (intranasal 5-MeO-DMT...…

atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health...…